This study, published in Frontiers in Pediatrics, investigates whether switching preterm infants from standard formula to extensively hydrolyzed protein formula (EHF) improves feeding outcomes when breast milk is unavailable. While EHF significantly reduced the incidence of feeding intolerance and necrotizing enterocolitis, it did not shorten hospital stays or accelerate growth, and it raised concerns regarding bone mineral density.
TL;DR
For preterm infants who cannot be breastfed, extensively hydrolyzed formula (EHF) significantly reduces feeding intolerance and the risk of necrotizing enterocolitis (NEC). However, it offers no advantage in growth rates or hospital discharge timing and may increase the risk of metabolic bone disease due to lower mineral content compared to standard preterm formulas.
What Problem Does This Paper Address?
Preterm infants (born at $\le$ 34 weeks) often suffer from immature digestive systems, leading to Feeding Intolerance (FI)—a condition where the gut cannot process milk effectively, causing gastric retention, vomiting, or abdominal distension. FI often forces clinicians to rely on parenteral nutrition (IV feeding), which carries risks like sepsis and liver dysfunction.
While breast milk is the gold standard, it isn't always available. Clinicians typically use Standard Preterm Formula (SPF), but there is a growing interest in Extensively Hydrolyzed Formula (EHF). In EHF, proteins are pre-broken down into short peptides and amino acids, theoretically making them easier to digest. The authors sought to determine if EHF actually improves clinical outcomes and growth compared to SPF.
Methods
The researchers conducted a prospective, randomized, single-blinded trial at Zhongda Hospital, China.
- Participants: 587 preterm infants (GA $\le$ 34 weeks) were initially enrolled; 370 completed the study (185 in the EHF group, 185 in the SPF group).
- Intervention: The observation group received EHF, while the control group received SPF until discharge from the Neonatal Intensive Care Unit (NICU).
- Follow-up: After discharge, both groups were switched to standard 0-to-6-month infant formula and monitored for six months to track physical growth (weight, length, and head circumference).
- Clinical Metrics: The team tracked the incidence of FI, Necrotizing Enterocolitis (NEC), time to reach full enteral nutrition (EN), and biochemical markers of bone health (calcium, phosphorus, and alkaline phosphatase).
Datasets
The "dataset" for this clinical study consisted of the medical records and follow-up data of the 370 premature infants who completed the trial. The study utilized the Statistical Package for Social Sciences (SPSS) version 22.0 for data analysis, employing F-tests, Mann–Whitney rank-sum tests, and chi-square tests to determine statistical significance.
Key Insights and Ideas
- Digestibility vs. Nutrient Density: EHF is a "double-edged sword." Because the proteins are hydrolyzed, the gut handles them better, leading to a 50% reduction in FI and a significant drop in NEC. However, the specific EHF used in this study had lower caloric and mineral density than the SPF.
- The Growth Neutrality: Despite the SPF group having more digestive issues, they grew at the same rate as the EHF group. This suggests that the higher nutrient density of SPF compensated for the interruptions caused by feeding intolerance.
- Bone Health Warning: At discharge, the EHF group showed lower serum phosphorus and higher alkaline phosphatase (ALP) levels. This is a clinical red flag for Metabolic Bone Disease (MBD) of prematurity, likely because the EHF was not as heavily fortified with minerals as the SPF designed specifically for preemies.
Key Results
- Feeding Intolerance: EHF group (14.1%) vs. SPF group (30.3%), $p < 0.01$.
- Necrotizing Enterocolitis (NEC): EHF group (2.2%) vs. SPF group (6.5%), $p < 0.05$.
- Hospitalization & Nutrition Timing: There was no significant difference in the time taken to reach full enteral nutrition, the duration of IV feeding, or the total length of hospital stay.
- Bone Markers: Serum phosphorus was lower in the EHF group (2.10 vs. 2.22 mmol/L), and ALP was significantly higher (254 vs. 220 IU/L), indicating poorer bone mineralization.
- Long-term Growth: No significant differences were found in weight, length, or head circumference at the 6-month follow-up.
Limitations and Future Work
The primary limitation noted was the nutrient disparity between the two formulas; the EHF provided only 66 kcal/100 ml compared to the higher-density SPF. This likely explains why EHF didn't lead to faster discharge or better growth despite better gut tolerance.
The authors suggest that future research should focus on using nutrient-enriched EHF or implementing a strategy where infants are transitioned to SPF once they reach full enteral nutrition to mitigate the risk of metabolic bone disease. Additionally, multi-center studies with larger cohorts are needed to confirm these findings across different populations.
Summary updated